MOSCOW, December 4. /TASS/. Russian Direct Investment Fund (RDIF) said on Friday it had signed an agreement on cooperation for the accelerated registration, production and distribution of the Russian Sputnik V anti-coronavirus vaccine with Kazakhstan’s Health Ministry.
“Thanks to the agreement between the RDIF and Kazakhstan, the population of this country will have access to the anti-coronavirus vaccine with the efficiency of more than 91%. Production of the Sputnik V vaccine that will be organized in Kazakhstan will make it possible to reduce logistic costs and ensure supplies of the vaccine to medical establishments in a short period of time. Apart from that, the agreements will make it possible to expand exchange of technologies, research and medical experience between our countries,” RDIF quoted its CEO Kirill Dmitriev as saying.
After Kazakhstan’s regulating agencies issue an approval, technology transfer will be carried out and material for the production of at least two million doses of the Sputnik V vaccine will be supplied to Kazakhstan.
On August 11, Russia registered the world’s first vaccine against the novel coronavirus. The vaccine, dubbed Sputnik V, was developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry. Its clinical trials were successfully completed in June-July. The Russian Health Ministry said on August 15 that production of the vaccine had been launched. The third, post-registration, stage of clinical tests began in Moscow on September 7. Volunteers were inoculated with the first dose of the vaccine on September 9. As many as 40,000 people are involved in the trials, with 10,000 of them being inoculated with a placebo.
According to the third phase results, the vaccine’s efficiency is 91.4%.
Currently, third phase tests are underway in Belarus, the United Arab Emirates, Venezuela, and a number of other countries, while second and third phase trials are being carried out in India.
Orders for more than 1.2 billion doses of the Sputnik V vaccine have come from more than 50 countries. International partners of the Russian Direct Investment Fund in India, Brazil, China, South Korea and in four more states will manufacture the vaccine.